Current immunotherapy of melanoma
- 1 March 2005
- journal article
- Published by Elsevier BV in Clinical and Applied Immunology Reviews
- Vol. 5 (2), 111-132
- https://doi.org/10.1016/j.cair.2005.01.002
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®Seminars in Cancer Biology, 2003
- Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2Melanoma Research, 2003
- Intra-Lesional rF-B7.1 Versus rF-TRICOM Vaccine in the Treatment of Metastatic CancerHuman Gene Therapy, 2003
- Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapyEuropean Journal of Immunology, 2002
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- Regulatory T Cells in AutoimmmunityAnnual Review of Immunology, 2000
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993